Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients

BACKGROUND: Right- (R) and left-sided (L) metastatic colorectal cancer (mCRC) exhibit different clinical and molecular features. Several retrospective analyses showed that survival benefit of anti-EGFR-based therapy is limited to RAS/BRAF wt L-sided mCRC patients. Few data are available about third-...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvatore, Lisa, Bensi, Maria, Vivolo, Raffaella, Zurlo, Ina Valeria, Dell’Aquila, Emanuela, Grande, Roberta, Anghelone, Annunziato, Emiliani, Alessandra, Citarella, Fabrizio, Calegari, Maria Alessandra, Ribelli, Marta, Basso, Michele, Pozzo, Carmelo, Tortora, Giampaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989252/
https://www.ncbi.nlm.nih.gov/pubmed/36895480
http://dx.doi.org/10.3389/fonc.2023.1125013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989252/
https://www.ncbi.nlm.nih.gov/pubmed/36895480
http://dx.doi.org/10.3389/fonc.2023.1125013

Ejemplares similares